Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
Strengthens investor syndicate with SV s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs for dementia and other inflammatory conditions.
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini s lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Therini Bio was co-founded by Dr. Katerina Akassoglou, PhD, based upon discoveries from her laboratory at Gladstone Institutes and also UC San Francisco that a cryptic epitope on fibrin, a blood-clotting factor, drives toxic chronic inflammation in the brain and t